These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38466821)

  • 21. Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients.
    Wan S; Huang C; Zhu X
    BMJ Open; 2019 Jul; 9(7):e030038. PubMed ID: 31315875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Huang R; Wang J; Wu W; Yan X; Wu C
    Hepatology; 2020 Jun; 71(6):2173-2174. PubMed ID: 31858599
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.
    Li X; Sheng L; Liu L; Hu Y; Chen Y; Lou L
    BMC Gastroenterol; 2020 Apr; 20(1):98. PubMed ID: 32272891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Statin for Hepatocellular Carcinoma Prevention Among Chronic Liver Disease Patients: A Systematic Review and Meta-analysis.
    Wong YJ; Qiu TY; Ng GK; Zheng Q; Teo EK
    J Clin Gastroenterol; 2021 Aug; 55(7):615-623. PubMed ID: 33606427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
    Goh MJ; Sinn DH
    Clin Mol Hepatol; 2022 Jul; 28(3):380-395. PubMed ID: 35021597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J; Iwakiri Y
    Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin Use is Associated with Decreased Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.
    Cho Y; Kim MS; Nam CM; Kang ES
    Sci Rep; 2019 Feb; 9(1):1467. PubMed ID: 30728421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.
    El-Serag HB; Johnson ML; Hachem C; Morgana RO
    Gastroenterology; 2009 May; 136(5):1601-8. PubMed ID: 19208359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
    Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
    J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.
    Simon TG; Chan AT
    Clin Liver Dis; 2020 Nov; 24(4):549-576. PubMed ID: 33012445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins and risk reduction in hepatocellular carcinoma: fact or fiction?
    Singh PP; Singh S
    J Clin Oncol; 2012 Jul; 30(20):2569-70; author reply 2570-2571. PubMed ID: 22689810
    [No Abstract]   [Full Text] [Related]  

  • 36. [Managing the complications of cirrhosis].
    Deltenre P; Mathurin P; Barraud H; Bronowicki JP; Jacquet E; Puche P; Jaber S; Navarro F; Pageaux GP
    Rev Prat; 2005 Sep; 55(14):1555-63. PubMed ID: 16255297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.
    Kim G; Jang SY; Nam CM; Kang ES
    J Hepatol; 2018 Mar; 68(3):476-484. PubMed ID: 29107150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant.
    Merkel M; Schneider C; Greinert R; Zipprich A; Ripoll C; Lammert F; Reichert MC
    Hepatol Commun; 2021 Oct; 5(10):1755-1766. PubMed ID: 34558822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins and portal hypertension: A tale of two models.
    Arab JP; Shah VH
    Hepatology; 2016 Jun; 63(6):2044-7. PubMed ID: 27015447
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.